Limits...
EGFR-targeted delivery of DOX-loaded Fe 3 O 4 @ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy

View Article: PubMed Central - PubMed

ABSTRACT

Multifunctional nanocomposites that have multiple therapeutic functions together with real-time imaging capabilities have attracted intensive concerns in the diagnosis and treatment of cancer. This study developed epidermal growth factor receptor (EGFR) antibody-directed polydopamine-coated Fe3O4 nanoparticles (Fe3O4@PDA NPs) for magnetic resonance imaging and antitumor chemo-photothermal therapy. The synthesized Fe3O4@PDA-PEG-EGFR-DOX NPs revealed high storage capacity for doxorubicin (DOX) and high photothermal conversion efficiency. The cell viability assay of Fe3O4@PDA-PEG-EGFR NPs indicated that Fe3O4@ PDA-PEG-EGFR NPs had no cell cytotoxicity. However, Fe3O4@PDA-PEG-EGFR-DOX NPs could significantly decrease cell viability (~5% of remaining cell viability) because of both photothermal ablation and near-infrared light-triggered DOX release. Meanwhile, the EGFR-targeted Fe3O4@PDA-PEG-EGFR-DOX NPs significantly inhibited the growth of tumors, showing a prominent in vivo synergistic antitumor effect. This study demonstrated the potential of using Fe3O4@PDA NPs for combined cancer chemo-photothermal therapy with increased efficacy.

No MeSH data available.


Related in: MedlinePlus

In vivo T2-weighted MR images.Notes: T2-weighted MR images of mice after intravenous injection with Fe3O4@PDA-PEG-EGFR NPs at 0, 12, and 24 h. Red circle indicates tumor position.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5391832&req=5

f8-ijn-12-2899: In vivo T2-weighted MR images.Notes: T2-weighted MR images of mice after intravenous injection with Fe3O4@PDA-PEG-EGFR NPs at 0, 12, and 24 h. Red circle indicates tumor position.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.

Mentions: The excellent in vitro MRI contrast performance of Fe3O4@PDA-PEG-EGFR NPs inspired us to study their applicability in vivo. Mice bearing DLD-1 tumors were intravenously injected with Fe3O4@PDA-PEG-EGFR NPs (200 µL, 100 µg/mL) and imaged by a 3.0-T clinical MR scanner at 0, 12, and 24 h. A strong darkening effect in the tumor area was observed in T2-weighted MR images at 24 h after injection (Figure 8), suggesting that Fe3O4@PDA-PEG-EGFR NPs could be used for MRI-guided cancer therapy.


EGFR-targeted delivery of DOX-loaded Fe 3 O 4 @ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy
In vivo T2-weighted MR images.Notes: T2-weighted MR images of mice after intravenous injection with Fe3O4@PDA-PEG-EGFR NPs at 0, 12, and 24 h. Red circle indicates tumor position.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5391832&req=5

f8-ijn-12-2899: In vivo T2-weighted MR images.Notes: T2-weighted MR images of mice after intravenous injection with Fe3O4@PDA-PEG-EGFR NPs at 0, 12, and 24 h. Red circle indicates tumor position.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
Mentions: The excellent in vitro MRI contrast performance of Fe3O4@PDA-PEG-EGFR NPs inspired us to study their applicability in vivo. Mice bearing DLD-1 tumors were intravenously injected with Fe3O4@PDA-PEG-EGFR NPs (200 µL, 100 µg/mL) and imaged by a 3.0-T clinical MR scanner at 0, 12, and 24 h. A strong darkening effect in the tumor area was observed in T2-weighted MR images at 24 h after injection (Figure 8), suggesting that Fe3O4@PDA-PEG-EGFR NPs could be used for MRI-guided cancer therapy.

View Article: PubMed Central - PubMed

ABSTRACT

Multifunctional nanocomposites that have multiple therapeutic functions together with real-time imaging capabilities have attracted intensive concerns in the diagnosis and treatment of cancer. This study developed epidermal growth factor receptor (EGFR) antibody-directed polydopamine-coated Fe3O4 nanoparticles (Fe3O4@PDA NPs) for magnetic resonance imaging and antitumor chemo-photothermal therapy. The synthesized Fe3O4@PDA-PEG-EGFR-DOX NPs revealed high storage capacity for doxorubicin (DOX) and high photothermal conversion efficiency. The cell viability assay of Fe3O4@PDA-PEG-EGFR NPs indicated that Fe3O4@ PDA-PEG-EGFR NPs had no cell cytotoxicity. However, Fe3O4@PDA-PEG-EGFR-DOX NPs could significantly decrease cell viability (~5% of remaining cell viability) because of both photothermal ablation and near-infrared light-triggered DOX release. Meanwhile, the EGFR-targeted Fe3O4@PDA-PEG-EGFR-DOX NPs significantly inhibited the growth of tumors, showing a prominent in vivo synergistic antitumor effect. This study demonstrated the potential of using Fe3O4@PDA NPs for combined cancer chemo-photothermal therapy with increased efficacy.

No MeSH data available.


Related in: MedlinePlus